{"id":"NCT01432444","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole","officialTitle":"Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2011-09-13","resultsPosted":"2015-03-27","lastUpdate":"2015-05-07"},"enrollment":493,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Aripiprazole (Abilify®) IM Depot Injection","otherNames":["ABILIFY®"]}],"arms":[{"label":"OPC-14597","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.","primaryOutcome":{"measure":"Number of Inpatient Psychiatric Hospitalization for Retrospective Period (Months 4-6) and Prospective Period (Months 4-6).","timeFrame":"Retrospective period Months 4-6; Prospective period Months 4-6","effectByArm":[{"arm":"Open-label Aripiprazole IM Depot Treatment Phase (Phase B)","deltaMin":91,"sd":0.6}],"pValues":[{"comp":"OG000","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":21},"locations":{"siteCount":124,"countries":["United States","Canada"]},"refs":{"pmids":["27531181","25347448","23663091"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":61,"n":431},"commonTop":["Akathisia","Insomnia","Weight increased"]}}